Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.39 |
| ▸ | CDK9 | P50750 | 5/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9506003 | 0.81 | GLA (0.38) | GLAPGK1PGK2ALDH1A1L3MBTL1 | |
| SCHEMBL5773683 | 0.80 | FDPS (0.38) | CYP19A1PGK1PGK2ALDH1A1L3MBTL1 | |
| SCHEMBL5403459 | 0.79 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1POLBMEN1KMT2A | |
| SCHEMBL478915 | 0.79 | CCNT1 (0.56) | MAOBMAOACYP19A1CCNT1CDK9 | |
| SCHEMBL2030867 | 0.78 | GLA (0.59) | MAOBMAOACYP19A1GLAPGK1 | |
| SCHEMBL2032607 | 0.76 | TSHR (0.50) | MAOBMAOACCNT1CDK9ALDH1A1 | |
| SCHEMBL2030119 | 0.75 | MAOB (0.48) | MAOBMAOACYP19A1GLAABHD6 | |
| SCHEMBL28386683 | 0.75 | MAOB (0.48) | MAOBMAOACYP19A1GLAABHD6 | |
| SCHEMBL2029319 | 0.73 | MAOA (0.46) | MAOBMAOACYP19A1CCNT1CDK9 | |
| SCHEMBL2052212 | 0.72 | CCNT1 (0.40) | MAOBMAOACYP19A1CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | MAOB 2330/4885MAOA 3295/4885CYP19A1 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.